Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,178.00    -4.00 (-0.18%)
Bid:
2,192.00
Ask:
2,220.00
Spread: 28.00 (1.277%)
Market Cap: £1.45b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Director/PDMR Shareholding

20 Sep 2011 15:07

RNS Number : 5938O
Genus PLC
20 September 2011
Ā 

20 September 2011

Ā 

Genus plc

Ā 

('Genus' or 'the Company')

Ā 

Director/PDMR Shareholding

Ā 

Ā 

Genus announces that of 117,359 ordinary shares of 10 pence each in the Company ("Ordinary Shares") which vested today in favour of Richard Wood, Chief Executive, under the Genus 2004 Performance Share Plan (the "Plan"), 117,359 Ordinary Shares were today sold on behalf of Richard Wood at a price ofĀ 1,000Ā pence per Ordinary Share.

Ā 

Richard Wood's direct shareholding in the Company stands atĀ 45,856Ā Ordinary Shares which representsĀ 0.08%Ā of the issued share capital of the Company which is currentlyĀ 60,239,150 Ordinary Shares.

Ā 

Genus also announces that ofĀ 46,927 Ordinary SharesĀ that vested today in favour of Ian Biggs, Head of Global Product & Business Strategy, under the Plan,Ā 46,927 Ordinary Shares were today sold on behalf ofĀ Ian BiggsĀ at a price ofĀ 1,000Ā pence per Ordinary Share.

Ā 

Ian Biggs'Ā direct shareholding in the Company stands atĀ 3,375Ā Ordinary Shares which representsĀ 0.01%Ā of the issued share capital of the Company. In addition, he remains the beneficial owner ofĀ 78,415Ā conditional nil-cost optionsĀ under the Plan.

Ā 

OfĀ 41,061Ā Ordinary Shares that vested today in favour of Thomas Philip Acton, Chief Operating Officer of Europe & The Far East, under the Plan, 31,061 Ordinary Shares were today sold on behalf of Thomas Philip Acton at a price ofĀ 1,000Ā pence per Ordinary Share.

Ā 

Thomas Philip Acton'sĀ direct shareholding in the Company now stands atĀ 31,104Ā Ordinary Shares which representsĀ 0.06%Ā of the issued share capital of the Company. In addition, he remains the beneficial owner of 78,415Ā conditional nil-cost optionsĀ under the Plan.

Ā 

Of 28,156 Ordinary Shares that vested today in favour of Ian Farrelly, Group Company Secretary & General Counsel, under the Plan, 28,156 Ordinary Shares were today sold on behalf of Ian Farrelly at a price ofĀ 1,000Ā pence per Ordinary Share.

Ā 

Ian Farrelly has no direct shareholding in the Company. He remains the beneficial owner of 61,462 conditional nil-cost optionsĀ under the Plan.

Ā 

Genus further announces that of 1,619 Ordinary Shares which vested today in favour of Bill Christianson, Chief Operating Officer, The Americas, under the Genus 2004 Executive Share Option Plan (the "ESOP"), 1,619 Ordinary Shares were today sold on behalf of Bill Christianson at a price of 1,000 pence per Ordinary Share.

Ā 

Bill Christianson has no direct shareholding in the Company and is the beneficial owner of 56,953 conditional nil-cost options and 18,970 market value share options.

Ā 

Of 6,673 Ordinary Shares which vested today in favour of David Crosby, Group Financial Controller, under the ESOP, 6,673 Ordinary Shares were today sold on behalf of David Crosby at a price of 1,000 pence per Ordinary Share.

Ā 

David Crosby has no direct shareholding in the Company and is the beneficial owner of 53,843 conditional nil-cost options.

Ā 

Ā 

For further information please contact:

Ā 

Cara Crichton

Assistant Company Secretary

Genus plc

Ā 

Tel: 01256 345996

Ā 

This information is provided by RNS
The company news service from the London Stock Exchange
Ā 
END
Ā 
Ā 
RDSURRSRANAKUAR
Date   Source Headline
13th May 202612:32 pmRNSDirector/PDMR Shareholding
1st May 20269:20 amRNSTotal Voting Rights
13th Apr 20265:59 pmRNSDirector/PDMR Shareholding
1st Apr 20269:40 amRNSDirector/PDMR Shareholding
10th Mar 20263:56 pmRNSNotification of Major Holdings
10th Mar 20263:56 pmRNSNotification of Major Holdings
4th Mar 202610:33 amRNSDirector/PDMR Shareholding
4th Mar 202610:08 amRNSDirector Declaration
27th Feb 202612:48 pmRNSDirector/PDMR Shareholding
26th Feb 20267:00 amRNSInterim Results
2nd Feb 202612:39 pmRNSBlock Listing Return
2nd Feb 202611:21 amRNSTotal Voting Rights
2nd Feb 20267:00 amRNSSuccessful formation of Chinese porcine JV
23rd Jan 20265:23 pmRNSPRP Regulatory Progress – Canada
16th Jan 20267:00 amRNSHalf Year Trading Update – Ahead of expectations
27th Nov 20257:00 amRNSDirector/PDMR Shareholding
19th Nov 202512:12 pmRNSResults of AGM
19th Nov 20257:00 amRNSNon-Executive Director Appointments
19th Nov 20257:00 amRNSAGM Trading Update
3rd Nov 202510:56 amRNSTotal Voting Rights
14th Oct 20254:02 pmRNSNotification of Major Holdings
10th Oct 20257:00 amRNSNotice of AGM
1st Oct 20259:47 amRNSTotal Voting Rights
25th Sep 20254:49 pmRNSDirector/PDMR Shareholding
24th Sep 202511:35 amRNSDirector/PDMR Shareholding
19th Sep 20252:39 pmRNSDirector/PDMR Shareholding
17th Sep 202512:14 pmRNSDirector/PDMR Shareholding
11th Sep 202512:20 pmRNSDirector/PDMR Shareholding
8th Sep 20254:05 pmRNSAdditional Listing
4th Sep 20257:00 amRNSPreliminary results
4th Sep 20257:00 amRNSAccelerated Chinese porcine JV formation
28th Aug 20254:57 pmRNSNotification of Major Holdings
19th Aug 20253:03 pmRNSNotification of Major Holdings
19th Aug 20257:00 amRNSNotification of Major Holdings
6th Aug 202510:51 amBUSHolding(s) in Company
4th Aug 202511:14 amRNSNotification of Major Holdings
1st Aug 202510:10 amRNSBlock Listing Six Monthly Return
1st Aug 202510:05 amRNSTotal Voting Rights
15th Jul 20257:00 amRNSFY25 Trading Update
9th May 20259:25 amRNSAppointment of Financial Adviser & joint Broker
1st May 20252:28 pmRNSTotal Voting Rights
30th Apr 20257:00 amRNSPRRS Resistant Pig – FDA Approval
25th Apr 20254:30 pmRNSNotification of Major Holdings
25th Apr 20254:28 pmRNSNotification of Major Holdings
2nd Apr 20255:08 pmRNSDirector/PDMR Shareholding
2nd Apr 20253:43 pmRNSNotification of Major Holdings
13th Mar 20257:00 amRNSAppointment of Chief Financial Officer Designate
3rd Mar 202511:32 amRNSTotal Voting Rights
28th Feb 20251:30 pmRNSDirector/PDMR Shareholding
27th Feb 20257:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.